The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.本發明係關於用於治療癌症之抗CD20抗體及BTK抑制劑的組合療法,尤其關於具有I型抗CD20抗體或去海藻糖基化人類化B-Ly1抗體及BTK抑制劑之CD20表現癌症的組合療法。